P  - Caution when used during pregnancy

L  - Caution when used during lactation

Molecule Info

 
Indication & Dosage Intravenous
Iron-deficiency anaemia in chronic renal failure
Adult: Doses are expressed in terms of elemental iron. Haemodialysis-dependent patient: 100 mg 1-3 times/wk during dialysis; dose to be given via slow inj over 2-5 minutes for not >3 times/wk to a cumulative total dose of 1000 mg; may continue at lowest effective dose to maintain target haemoglobin, haematocrit and iron storage parameters. Peritoneal dialysis-dependent patient: Slow IV infusion at the following schedule: Two infusions of 300 mg each over 90 minutes 14 days apart followed by a single 400 mg infusion over 2.5 hours 14 days later (total cumulative dose: 1000 mg in 3 divided doses). Nondialysis-dependent patient: 200 mg via slow inj over 2-5 minutes on 5 different occasions within a 14-day period. Total cumulative dose: 1000 mg in 14-day period. 
Child: ≥2 yr: Haemodialysis-dependent patients: To correct deficiency: 1 mg/kg/dose per dialysis session (max: 100 mg); Maintenance: 0.3 mg/kg/dose per dialysis session (max: 100 mg). Dose to be given via slow IV inj over 2-5 minutes; can be administered through dialysis line.

Reconstitution: May be administered via the dialysis line as an undiluted solution or by diluting 100 mg in a max of 100 mL normal saline. Doses ≥200 mg should be diluted in a max of 250 mL normal saline.
Incompatibility: Not to be mixed with other medications.
Contraindications Hypersensitivity. Evidence of iron overload. Anaemia not caused by iron deficiency. History of asthma, eczema, anaphylaxis, or other allergic disorders.
Special Precautions Regular monitoring of haematologic parameters is needed to prevent iron overload. Periodic monitoring of haemoglobin, haematocrit, serum ferritin and transferrin saturation is recommended. Serum iron values can be reliably obtained 48 hr after IV admin. May take about 4 wk of treatment to see increased serum iron and ferritin. Caution during admin to reduce risk of hypotension and vascular flushing. Safety and efficacy have not been established in paediatrics. Caution when used in pregnant or lactating women.
Adverse Drug Reactions CV effects such as chest pain or tightness, shock, MI, hypertension, tachycardia, bradycardia, and arrhythmias. Rashes, urticaria, purpura, and pruritus. GI disturbances, haematuria, dyspnoea, and taste disturbance.
Potentially Fatal: Anaphylaxis.
Drug Interactions May reduce the serum levels of cefdinir; stools may appear red due to the formation of an insoluble iron-cefdinir complex. May reduce the serum levels of eltrombopag. May decrease absorption of phosphate supplements. Concurrent use with trientine may result in reduction of serum levels of iron sucrose and/or trientine.
Potentially Fatal: May reduce the serum levels of cefdinir; stools may appear red due to the formation of an insoluble iron-cefdinir complex. May reduce the serum levels of eltrombopag. May decrease absorption of phosphate supplements. Concurrent use with trientine may result in reduction of serum levels of iron sucrose and/or trientine.

Pregnancy Category (US FDA) Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1sttrimester (and there is no evidence of a risk in later trimesters).
Storage Intravenous: Vial: Store at 25°C. Diluted solutions are stable for 48 hr at room temperature or under refridgeration.
Pharmacology Ferric hydroxide sucrose complex is a source of iron that is used in iron-deficiency anaemia whereby oral iron is ineffective or impractical. Iron sucrose is broken down into iron and sucrose by the reticuloendothelial system. The released iron increases serum iron concentrations and is incorporated into haemoglobin.
Distribution: Volume of distribution: Healthy adults: 7.9 L.
Metabolism: Dissociated into iron and sucrose by the reticuloendothelial system.
Excretion: Rapidly cleared from the plasma after IV inj; terminal half-life: 6 hr. About 5% of a dose is excreted via kidneys within the 1st 4 hr.

Brand/Product Info


Total Products : 12            
Brand Name Manufacturer/Marketer Composition Dosage Form Pack Size & Price
DEFIRON IV Square Pharmaceuticals Ltd. Iron Sucrose 20mg/ml IV Injection 1x1's: 301.14 MRP
Ferimax Incepta Pharmaceuticals Limited Iron Sucrose USP 100mg/5ml IV Injection 1x1's:MRP 300 Tk
FEROVEN Orion Pharma Ltd. Iron sucrose injection USP equivalent to elemental iron 100mg/5ml Injection 5ml ampoule: 301.14 MRP
FEROVEN I/V Orion Pharma Ltd. Iron sucrose injection USP equivalent to elemental iron 100mg/5ml Infusion 5ml amp. with 100ml Normal Saline: 326.27 MRP
HEMOFER Popular Pharmaceuticals Ltd. Iron sucrose injection USP equivalent to elemental iron 100mg/5ml Injection 5ml amp. x2's: 602.26 MRP
HEMOFER I/V Popular Pharmaceuticals Ltd. Iron sucrose injection USP equivalent to elemental iron 100mg/5ml Infusion 5ml amp. with 100ml Normal Saline: 325.00 MRP
INOFAR Aristopharma Ltd. Iron sucrose injection USP equivalent to elemental iron 100mg/5ml Injection 5ml amp. x2's: 600.00 MRP
UNIFER Ziska Pharmaceuticals Ltd. Iron sucrose injection USP equivalent to elemental iron 100mg/5ml Injection 5ml ampoule: 300.00 MRP
VENIRON Injection Beximco Pharmaceuticals Ltd Iron Sucrose USP eq. to elemental Iron 100mg/5ml Injection 1's: 300.00 MRP
VENOFER Vifor International/UniMed Iron sucrose injection USP equivalent to elemental iron 100mg/5ml Injection 5ml amp. x2's: 1610.75 MRP
XENOFER 100 Beacon Pharmaceuticals Limited Iron sucrose injection USP equivalent to elemental iron 100mg/5ml Injection 5ml amp. x2's: 602.26 MRP
XENOFER 50 Beacon Pharmaceuticals Limited Iron sucrose injection USP equivalent to elemental iron 50mg/5ml ampoule Injection 5ml ampoule: 274.00 MRP